Refine your search

Search Results within category "Injury, Trauma & Emergency Medicine"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Injury, Trauma & Emergency Medicine"


4 Study Matches

Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults

This pilot study aims to assess the feasibility of providing immunonutrition supplementation to older burn patients (age 65 and older) and its impact on burn wound healing. Supplements containing arginine and omega 3 fatty acids have been shown to have beneficial effects on healing in other types of wounds but data within the burn population remains limited. 20 participants will be randomized into two arms, immunonutrition or conventional supplement and can expect to be on study for 3 months.
Rebecca Busch, MD
All
65 Years and over
N/A
This study is NOT accepting healthy volunteers
NCT04725071
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Subject has partial of full thickness thermal injury of 5-15% of total body surface area (TBSA)
• Subject has an inpatient admission for their burn
• Subject or authorized decision maker understands the study procedures and can provide informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
Exclusion Criteria:

• Subject with inhalation injury and/or intubation
• Subject receiving immunosuppressive medications including chronic steroids, immune modulating medications, and chemotherapy prior to admission
• Subject with pre-existing severe chronic liver disease or end stage renal disease
Burn Wound, Burns and corrosions of external body surface, Burn of unspecified body region, unspecified degree, Burns involving less than 10% of body surface, Burns involving 10-19% of body surface area, Injury, Trauma & Emergency Medicine, Food & Nutrition, Skin & Dermatology
  Share Study Information
  Contact by Email
  Contact by Phone
  See more information

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb Biodegradable Temporizing Matrix (BTM).
Angela Gibson
All
21 Years to 70 Years old
N/A
This study is NOT accepting healthy volunteers
NCT04090424
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1. Provide written informed consent directly or via legal representative prior to any clinical study procedures being performed 2. Willing to comply with all study procedures and expects to be available for the duration of the study 3. Male and females ≥ 21 years of age and ≤ 70 years of age 4. Patients with deep dermal or full thickness burns between 5% and 50%, inclusive, of their total body surface area (TBSA). Types of burns include the following:
• Scalding including from hot water, cooking oil, grease
• Flame
• Flash
• Contact 5. Subjects who have staged surgical procedures planned e.g., one procedure to excise the burn injury and a later procedure to prepare the wound bed and apply an autologous skin graft. 6. The minimum total area across all lesions to have NovoSorb® BTM applied is 5% BSA 7. Females, who are non-pregnant, naturally postmenopausal, or who agree to use effective contraceptive methods throughout the course of the study.
Exclusion Criteria:
1. Has a known hypersensitivity to polyurethane 2. Only a non-burn injury has been experienced by the subject including soft-tissue degloving and friction burn/crush, i.e., road rash 3. Multiple traumas, i.e., significant traumatic injury to a solid organ in addition to skin 4. Presence of a medical condition with a life expectancy of less than 12 months, such as advanced malignancy 5. Presence of a medical condition that might interfere with treatment evaluation; or require a change in therapy including but not limited to, significant immune deficiency, or skin or vascular diseases in the area of the wound 6. For females
•has known or suspected pregnancy, planned pregnancy, or during lactation 7. Has exposure to any other investigational agent within the last 6 months 8. Has exposure to any other treatment/device that will interfere with NovoSorb® BTM integration 9. Anticipated inability to perform wound care and follow-up procedures 10. Anticipates of a level of non-compliance 11. The use of off-label treatments for full-thickness / deep-dermal burns is not permitted 12. Clinical signs of wound infection at areas to be potentially treated using NovoSorb® BTM that in the opinion of the investigator may compromise safety and study objectives 13. The use of NovoSorb® BTM on the face and in the perineum area is not permitted
Burns, Burns and corrosions of external body surface, Injury, Trauma & Emergency Medicine
  Share Study Information
  Contact by Email
  Contact by Phone
  See more information

CHIlled Platelet Study "CHIPS" (CHIPS)

A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Joseph Connor
All
29 Days to 84 Years old
Phase 3
This study is NOT accepting healthy volunteers
NCT04834414
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age greater than 28 days and less than 85 years
• Planned complex cardiac surgery with planned use of cardiopulmonary bypass
Exclusion Criteria:

• Expected order for washed or volume reduced platelets
• Patient with known anti-platelet antibodies
• Platelet transfusion refractoriness due to anti-HLA antibodies
• Known or suspected pregnancy
• Previously randomized in this study
• Conscious objection or unwillingness to receive blood products
• Known IgA deficiency
• Known congenital platelet disorder
• Known congenital bleeding disorder
• Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
• Patients intended to receive whole blood either intra-operative or post-operative for bleeding
• Platelet transfusion (of any type) within 24 hours prior to the date of surgery
• Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Other acute ischemic heart diseases, Heart failure, Complications of heart transplant, Congenital malformation of heart, unspecified, Heart & Vascular, Acute Blood Loss
  Share Study Information
  Contact by Email
  Contact by Phone
  See more information

The Acute Burn ResUscitation Multicenter Prospective Trial (ABRUPT2)

This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Angela Gibson
All
18 Years and over
N/A
This study is NOT accepting healthy volunteers
NCT04356859
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age ≥ 18 years
• Total burn size (second and third degree) is ≥ 25% of the TBSA
• Burn center admission within 12 hours of injury.
• There is a plan for formal fluid resuscitation.
Exclusion Criteria:

• Significant associated trauma
• High voltage (≥ 1000 volts) electrical burns
• Burn wound excision surgery within 48 hours from injury
• Fresh frozen plasma (FFP) given at any time ≤ 48 hours from injury
• Hypertonic saline (HTS) given at any time ≤ 48 hours from injury
• Hydroxyethyl starch (HES) given at any time ≤ 48 hours from injury
• High dose Vitamin C infusion given at any time ≤ 48 hours from injury
• Administration of human albumin prior to randomization
• Palliative comfort measures are instituted ≤ 48 hours from injury
• Pregnancy
• Pre-injury chronic renal insufficiency equal to or greater than stage 3
• Pre-injury chronic hepatic disease (Child-Pugh B or C)
• Pre-injury left ventricular (LV) dysfunction (echocardiography LV grade II-IV or ejection fraction ≤ 35%)
Burn Injury, Burn of unspecified body region, unspecified degree, Injury, Trauma & Emergency Medicine, Skin & Dermatology
  Share Study Information
  Contact by Email
  Contact by Phone
  See more information